Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardio Diagnostics Holdings (CDIO) EBIT (2021 - 2025)

Historic EBIT for Cardio Diagnostics Holdings (CDIO) over the last 5 years, with Q3 2025 value amounting to -$1.7 million.

  • Cardio Diagnostics Holdings' EBIT fell 2147.89% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.5 million, marking a year-over-year increase of 2209.64%. This contributed to the annual value of -$8.4 million for FY2024, which is 1551.16% down from last year.
  • Per Cardio Diagnostics Holdings' latest filing, its EBIT stood at -$1.7 million for Q3 2025, which was down 2147.89% from -$1.7 million recorded in Q2 2025.
  • In the past 5 years, Cardio Diagnostics Holdings' EBIT registered a high of -$397.0 during Q2 2021, and its lowest value of -$4.2 million during Q1 2024.
  • Its 5-year average for EBIT is -$1.4 million, with a median of -$1.5 million in 2023.
  • In the last 5 years, Cardio Diagnostics Holdings' EBIT tumbled by 19812770.78% in 2022 and then soared by 6078.54% in 2025.
  • Cardio Diagnostics Holdings' EBIT (Quarter) stood at -$145321.0 in 2021, then plummeted by 1536.42% to -$2.4 million in 2022, then surged by 35.16% to -$1.5 million in 2023, then grew by 1.66% to -$1.5 million in 2024, then decreased by 12.87% to -$1.7 million in 2025.
  • Its EBIT was -$1.7 million in Q3 2025, compared to -$1.7 million in Q2 2025 and -$1.6 million in Q1 2025.